Comparative Pharmacology
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PATHILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PATHILON.
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE vs PATHILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
Anticholinergic agent that competitively inhibits muscarinic acetylcholine receptors, decreasing gastrointestinal motility and gastric acid secretion.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
1-2 mg orally every 4-6 hours; maximum 12 mg/day. Alternatively, IM: 1-2 mg every 4-6 hours.
None Documented
None Documented
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Terminal elimination half-life approximately 2-4 hours; may be prolonged in elderly or patients with hepatic/renal impairment.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Primarily renal (50-70% as unchanged drug and metabolites); biliary/fecal (20-30%); minor metabolism via hepatic ester hydrolysis.
Category D/X
Category C
Anticholinergic
Anticholinergic